RT Journal Article
SR Electronic
T1 Epidemic graph diagrams as analytics for epidemic control in the data-rich era
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.10.10.22280897
DO 10.1101/2022.10.10.22280897
A1 Valdano, Eugenio
A1 Colombi, Davide
A1 Poletto, Chiara
A1 Colizza, Vittoria
YR 2022
UL http://medrxiv.org/content/early/2022/10/11/2022.10.10.22280897.abstract
AB COVID-19 highlighted how modeling is an integral part of pandemic response. But it also exposed fundamental methodological challenges. As high-resolution data on disease progression, epidemic surveillance, and host behavior are now available, can models turn them into accurate epidemic estimates and reliable public health recommendations? Take the epidemic threshold, which estimates the potential for an infection to spread in a host population, quantifying epidemic risk throughout epidemic emergence, mitigation, and control. While models increasingly integrated realistic host contacts, no parallel development occurred with matching detail in disease progression and interventions. This narrowed the use of the epidemic threshold to oversimplified disease and control descriptions. Here, we introduce the epidemic graph diagrams (EGDs), novel representations to compute the epidemic threshold directly from arbitrarily complex data on contacts, disease and control efforts. We define a grammar of diagram operations to decompose, compare, simplify models, extracting new theoretical understanding and improving computational efficiency. We test EGDs on two public health challenges, influenza and sexuallytransmitted infections, to (i) explain the emergence of resistant influenza variants in the 2007-2008 season, and (ii) demonstrate that neglecting non-infectious prodromic stages biases the predicted epidemic risk, compromising control. EGDs are however general, and increase the performance of mathematical modeling to respond to present and future public health challenges.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study was partially supported by: the ANR projects COSCREEN (ANR-21-CO16-0005) and DATAREDUX (ANR-19-CE46-0008-03) to VC; EU Horizon 2020 grant MOOD (H2020-874850) to EV, CP, VC.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data (parameter estimates) are reported in the manuscript and supplementary information.